Trial Profile
Combination Capecitabine (Xeloda) and ABI-007 (Abraxane, Nanoparticle Albumin-Bound Paclitaxel) Chemotherapy as Neoadjuvant Treatment of Locally Advanced, Operable Breast Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II/III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Paclitaxel (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 15 Feb 2021 Status changed from recruiting to withdrawn prior to enrolment.
- 24 Nov 2006 New trial record.